Merck demonstrated healthy revenue growth over recent years with consistent improvement in net income and earnings per share until the latest quarter. However, the Q1 2026 results showed a material operating loss and negative net income, driven by a large jump in R&D and operating expenses, which is a departure from prior positive earnings trends.

Revenues have grown moderately, with FY 2025 revenue at $64.9 billion up from $64.2 billion in 2024, reflecting sustained demand for core products. The latest quarter revenue stands at $16.3 billion, roughly stable sequentially but slightly elevated compared to prior quarterly averages, suggesting steady top-line performance despite cost pressures.

Historically, gross margins have been strong (~72-76%) reflecting pricing power and efficient production. Operating margins were healthy over recent years (~31-38%) but collapsed to negative -11.6% in the latest quarter, primarily due to increased R&D and SG&A expenses impacting operating income. Net margin similarly deteriorated sharply to -26% in Q1 2026 from ~28% in FY 2025.

Earnings quality was solid through 2025 with positive free cash flow supported by operational efficiency. The recent loss quarter suggests one-off impacts or intensified investment phases affecting earnings quality temporarily. No significant signs of accounting manipulation are evident, but earnings are currently pressured by increased investment expenses.

Year-over-year revenue grew slightly from $64.2 billion in 2024 to $64.9 billion in 2025, a modest ~1% increase signaling a mature but still growing revenue base. Quarterly revenue in Q1 2026 was up about 4% sequentially compared to Q4 2025, indicating stability.

EPS grew from $6.76 in 2024 to $7.30 in 2025, about 7.9% annual growth reflecting profitable expansion. However, Q1 2026 EPS plunged to -$1.72, marking a sharp reversal related to cost spikes and operational losses.

Growth is driven by new product launches, increased sales in oncology and vaccines, and ongoing R&D leading to a pipeline of innovative therapies. Expansion into emerging markets also supports growth.

Growth appears to be largely organic, with sustainable revenue streams backed by R&D investments. The recent drop in profitability may reflect front-loaded investment or costs related to product development cycles rather than acquisitive growth.

Gross margins remained robust historically at 72-76%, but operating and net margins deteriorated in the latest quarter to negative territory due to steep rises in operating expenses, with operating margin dropping from about 37% in FY 2025 to -11.6% in Q1 2026.

Return on equity (ROE) and return on assets (ROA) have been strong during the last full fiscal year, supported by above 20% net income margins, but likely under pressure in the recent quarter given the loss recorded. The exact percentage ROI metrics are not disclosed for Q1 2026 but likely contracted significantly.

While the recent margin compression is concerning, it is likely temporary given Merck's strong market positioning and cash flow generation. If R&D investments lead to new approvals, margins should recover long-term, but near-term margin sustainability is uncertain.